Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153901 | 1.00 | HRH4 (0.51) | HRH4PRKCQPLD1DPP4DPP8 | |
| SCHEMBL3154404 | 1.00 | HRH4 (0.51) | HRH4PRKCQPLD1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL1402090 | 0.98 | HRH4 (0.50) | HRH4PRKCQPLD1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL1402092 | 0.98 | HRH4 (0.50) | HRH4PRKCQPLD1DPP4DPP8 | |
| SCHEMBL29683665 | 0.90 | PRKCQ (0.53) | HRH4PRKCQPLD1DPP4 | |
| SCHEMBL723065 | 0.90 | PRKCQ (0.53) | HRH4PRKCQPLD1DPP4 | |
| SCHEMBL29683564 | 0.89 | PLD1 (0.58) | PRKCQPLD1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL243658 | 0.89 | PLD1 (0.58) | PRKCQPLD1GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL243428 | 0.88 | PLD1 (0.56) | PRKCQPLD1GRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL17557596 | 0.88 | PLD1 (0.56) | PRKCQPLD1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| EP-3383859-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-04-29 | — | — | EP | disclosed |
| EP-3526206-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-21 | — | — | EP | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| US-10227329-B2 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227329-B2 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| CN-101384583-A | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI AVENTIS (FR) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987020-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008052671-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007093364-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| US-7105682-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7102009-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060194848-A1 | e.g. 2-(1H-indazol-6-ylamino)-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide; angiogenesis inhibitors, antiproliferative or anticarcinogenic agents | AMGEN INC. | 2006-08-31 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | USP30, USP1, USP20 | HRH4 4007/4885PRKCQ 764/4885PLD1 1318/4885 |
| US-10227329-B2 | Compounds useful for treating disorders related to RET | RET, EYA2, HRAS | HRH4 2585/4885PRKCQ 241/4885PLD1 1941/4885 |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | HRH4 512/4885PRKCQ 1864/4885PLD1 183/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | HRH4 512/4885PRKCQ 1864/4885PLD1 183/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HRH4 206/4885PRKCQ 4182/4885PLD1 3042/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HRH4 206/4885PRKCQ 4182/4885PLD1 3042/4885 |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | USP30, USP1, USP20 | HRH4 4007/4885PRKCQ 764/4885PLD1 1318/4885 |
| US-20060194848-A1 | e.g. 2-(1H-indazol-6-ylamino)-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide; angiogenesis inhibitors, antiproliferative or anticarcinogenic agents | NNT, NAMPT, NNMT | HRH4 2034/4885PRKCQ 2793/4885PLD1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.